QUOTE AND NEWS
Benzinga  Mar 29  Comment 
Amid a raging opioid epidemic, Egalet Corp (NASDAQ: EGLT) soared as high as 13 percent Wednesday after the U.S. Food and Drug Administration permitted it to distribute promotional material highlighting the abuse-deterrent properties of intranasal...
Benzinga  Mar 29  Comment 
Egalet Corp (NASDAQ: EGLT) shares are trading higher by $0.31 (7 percent) at $5.15 in Wednesday's session. Before the open, the company announced its challenge to the FDA for MorphBond exclusivity is still being considered. That news instigated...
Benzinga  Mar 15  Comment 
“After two days of data presentations, the FDA Advisory Committee voted 18-8 (1 abstention) that the benefits of reformulated, crush-resistant Opana ER no longer outweigh the risks,” Cantor Fitzgerald’s Chiara Russo said in a note. The...
Benzinga  Mar 13  Comment 
Cantor Fitzgerald cut its price target on Egalet Corp (NASDAQ: EGLT) shares by $2 to $13 on the delay of clinical progress for Egalet-002, which is now expected to file an NDA in 2019 versus previous guidance of mid-2017. However, Chiara Russo...
Benzinga  Mar 13  Comment 
Egalet Corp (NASDAQ: EGLT), the specialty pharmaceutical company that develops and commercializes treatments for pain and other conditions, likely got "trolled" during its conference call. During the conference call's Q&A session, an analyst...
newratings.com  Jan 11  Comment 
SAN DIEGO (dpa-AFX) - The following are the biotech stocks that made their way onto the Day's Gainers & Losers' list of January 10, 2017. Signal Genetics Inc. (SGNL) Gained 264.93% to close Tuesday's trading at $17.48. News: No...
Motley Fool  Jan 10  Comment 
The U.S. Food and Drug Administration approved the company's new opioid painkiller, but denied two important label claims.
Benzinga  Jan 10  Comment 
Egalet Corporation (NASDAQ: EGLT) shares are trading lower by $1.50 (20 percent) at $6.88 in Tuesday's session. The issue soared to $10.00 in Monday's session after the company received regulatory approval for ARYMO ER for pain management. The...




Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki